⚠CONFIDENTIEL — Document propriétaire LumiSurg. Usage interne uniquement. Ne pas diffuser.
📊 Marché

Étude de marché — NIR/NIR-II agents de contraste chirurgicaux

📅 24 avril 2026📖 15 min de lecture📝 ~3 036 mots

Note de recherche structurée sur le marché mondial des agents de contraste NIR/NIR-II à usage opératoire. Aperçu réglementaire, acteurs clés, tendances commerciales et priorités stratégiques LumiSurg.

LumiSurg Market Research: NIR / NIR-II Surgical Contrast Agents

Date: 2026-04-24

Executive summary

Surgical fluorescence imaging is already a real market, but today it is still dominated by NIR-I workflows, indocyanine green (ICG), and installed camera platforms that were originally optimized for perfusion, biliary anatomy, and lymphatic mapping. NIR-II is strategically important because it offers lower tissue scattering, lower autofluorescence, and better deep-tissue contrast, but the commercial market for true NIR-II operative dyes remains early and fragmented.

For LumiSurg, the immediate opportunity is not to assume a mature standalone NIR-II dye market exists today. The better position is to treat NIR-II as an emerging premium layer on top of the broader fluorescence-guided surgery ecosystem: first via data centralization, clinical intelligence, and regulatory monitoring; then via targeted asset scouting, device compatibility mapping, and partnership development around next-generation dyes.

1. Market overview

1.1 What the market looks like today

  • NIR-I generally refers to fluorescence imaging in the ~700-900 nm window.
  • NIR-II generally refers to imaging in the ~1000-1700 nm window.
  • The commercial surgical market in 2026 is still overwhelmingly NIR-I-led, especially around ICG-enabled perfusion imaging, biliary anatomy, lymphatic mapping, and selected oncology workflows.
  • NIR-II is technologically attractive, but most operative use remains translational, pilot-stage, or dependent on tail-emission strategies from already familiar dyes such as ICG or methylene blue (MB).

1.2 Why NIR-II matters

Compared with NIR-I, NIR-II can improve signal-to-background ratio in tissue because photon scattering and tissue autofluorescence are lower at longer wavelengths. In practical surgical terms, that can translate into better visualization depth, cleaner tumor/background separation, and more robust imaging in challenging fields such as obese patients, inflamed tissue, or margin assessment under blood-rich conditions.

The problem is not scientific relevance. The bottleneck is ecosystem readiness:

  • few approved or late-stage operative dyes designed specifically for NIR-II;
  • limited standardization of NIR-II-capable OR hardware;
  • sparse reimbursement pathways tied to fluorescence-specific outcome improvement;
  • manufacturing and toxicology burden for novel fluorophores;
  • regulatory complexity when drugs, devices, and software must work together.

1.3 Public market-size signals

Public market reports do not isolate a clean "NIR-II surgical dye" revenue line. The best available view is to triangulate from adjacent markets:

Market scope Base year Forecast year Estimate
Fluorescence-guided surgery systems 2023 2030 USD 92.7M in 2023; 15.97% CAGR (Grand View Research)
Fluorescence-guided surgery systems 2024 2030 USD 208.6M in 2024 to USD 454.9M in 2030; 13.9% CAGR (Research and Markets)
Broader near-infrared imaging market 2024 2030 USD 2.24B in 2024 to USD 2.82B in 2030; 3.9% CAGR (Grand View Research)
Broader near-infrared imaging market 2025 2030 USD 1.25B in 2025 to USD 2.08B in 2030; 10.6% CAGR (MarketsandMarkets)

1.4 LumiSurg interpretation

  • The overall fluorescence-guided surgery market is growing at a healthy double-digit rate.
  • Reported market size varies materially because analysts define the market differently: systems only, systems plus reagents, all NIR imaging, or narrower surgical subsets.
  • The commercially meaningful market through 2030 is still likely to be led by NIR-I hardware and agents.
  • NIR-II should be viewed as a high-upside emerging segment rather than a mature standalone market category.

2. Key contrast agents

2.1 Agent landscape at a glance

Agent Window Current status Main surgical use cases LumiSurg view
ICG (indocyanine green) NIR-I with useful tail emission into NIR-II Approved and entrenched Perfusion, vascular assessment, biliary anatomy, lymphatic mapping, some oncology workflows The dominant incumbent and the practical bridge into NIR-II workflows
Methylene blue (MB) NIR-I; also relevant as an NIR-II-capable fluorogenic scaffold in newer work Approved drug; fluorescence-surgery use is often off-label Ureter identification, lymphatics, selected structure mapping Useful for anatomy-specific workflows but less standardized than ICG
IRDye 800CW NIR-I Investigational; often used in targeted conjugates Tumor-targeted fluorescence, especially with antibody/ligand conjugates Strong translational platform, not yet a routine marketed surgical dye
ZW800-1 / nizaracianine NIR-I-edge zwitterionic fluorophore Investigational Ureter visualization and structure mapping Important bridge candidate because of renal clearance and clean background
Pafolacianine (CYTALUX / OTL38) NIR-I targeted optical agent FDA approved Ovarian lesions and pulmonary lesions The clearest regulatory precedent for targeted operative fluorophores
Next-generation NIR-II dyes NIR-II Mostly preclinical to early clinical Margin assessment, deep tumor detection, multiplexed image guidance Highest long-term value, but still early on CMC, safety, and workflow standardization

2.2 ICG

ICG remains the market anchor. It is already approved in the United States for fluorescence imaging of vessels and tissue perfusion, extrahepatic biliary ducts, and lymphatic mapping in selected cancers. Because it is cheap, known, and widely supported by installed devices, it defines the operational baseline for fluorescence-guided surgery.

For NIR-II strategy, ICG matters twice:

  • it is the incumbent NIR surgical dye that every hospital already understands;
  • its tail emission beyond 1000 nm makes it a practical translational bridge into NIR-II imaging without immediately requiring a brand-new pharmacology stack.

Weaknesses:

  • nonspecific signal;
  • short plasma residence;
  • concentration and workflow variability;
  • limited tumor specificity unless used with indirect accumulation strategies.

2.3 Methylene blue

MB is clinically familiar and attractive for ureter and anatomy visualization because of renal handling and strong operative familiarity. In the fluorescence literature, MB also appears in NIR-II discussions because its chemistry can be pushed into longer-wavelength applications or inspire clinically acceptable NIR-II fluorogenic approaches.

Its challenge is that MB is not a clean, standardized fluorescence-guided surgery product category in the same way ICG is. Adoption is therefore more protocol-dependent and institution-specific.

2.4 IRDye 800CW

IRDye 800CW is one of the most important translational scaffolds in fluorescence-guided oncology. It is commonly attached to antibodies or ligands such as panitumumab or cetuximab to create tumor-targeted probes, especially in head and neck, pancreatic, and other solid tumors.

Strategically, IRDye 800CW matters because it demonstrates where the field wants to go:

  • away from purely anatomical or perfusion imaging;
  • toward receptor-targeted lesion detection;
  • toward margin assessment and residual disease detection.

Commercially, however, it remains mainly a clinical-development and investigator-led platform rather than a fully established approved surgical dye franchise.

2.5 ZW800-1 / nizaracianine

ZW800-1, now also referred to as nizaracianine in recent clinical material, is one of the more credible investigational dyes for intraoperative ureter visualization. Its value proposition is clean renal excretion, low nonspecific background, and compatibility with existing fluorescence systems in abdominal and pelvic surgery.

This is a strong example of a high-value niche contrast agent: not a broad pan-surgical dye, but a structure-specific product that solves a real operating-room problem with clear medico-legal relevance.

2.6 Pafolacianine (CYTALUX / OTL38)

Although not explicitly requested in the brief's agent list, pafolacianine is too important to omit. It is the leading regulatory precedent for targeted fluorescence surgery in the U.S. market. CYTALUX is FDA approved for intraoperative identification of malignant ovarian lesions and malignant and non-malignant pulmonary lesions in adults with known or suspected cancer in the lung.

For LumiSurg, pafolacianine is strategically important because it validates three things:

  • targeted fluorescent drugs can achieve approval;
  • oncology is the most attractive near-term value pool beyond ICG;
  • operative dye companies can create value even before true NIR-II dominance arrives.

2.7 Next-generation NIR-II dyes

The next wave includes:

  • true NIR-II small molecules;
  • activatable fluorophores that switch on in tumor microenvironments;
  • targeted conjugates designed for specific receptors or enzymes;
  • engineered formulations and nanoparticles that extend brightness, circulation, or tumor contrast.

The key technical hurdles are consistent:

  • brightness in aqueous biological environments;
  • pharmacokinetics suitable for same-day surgery;
  • scalable GMP manufacturing;
  • toxicology packages acceptable for regulatory review;
  • compatibility with ambient-light surgical imaging systems.

3. Clinical applications

3.1 Oncology and tumor-margin work

This is the most important long-term application for NIR-II and targeted fluorophores. Surgeons want better detection of occult lesions, better margin visualization, and cleaner differentiation between tumor and normal tissue. Today, that need is partly addressed by ICG in nonspecific workflows and more specifically by targeted investigational agents and pafolacianine.

NIR-II is especially attractive here because oncology benefits most from deeper penetration, lower scattering, and potentially cleaner lesion contrast. If a true NIR-II targeted dye becomes practical, oncology is the most likely first premium market.

3.2 Vascular surgery and perfusion

Perfusion imaging is already a commercial reality, largely driven by ICG and device ecosystems such as Stryker SPY and Intuitive Firefly. This application is operationally mature, easy to explain clinically, and linked to outcomes such as flap viability and anastomotic assessment.

NIR-II may improve quantification and tissue-depth performance, but it will need to beat a deeply embedded ICG-based workflow.

3.3 Lymph node mapping

Lymphatic mapping is a core established use case for ICG and remains commercially important in gynecologic and breast procedures. The value proposition is strong because the clinical workflow is clear, surgeon training is manageable, and the incremental hardware burden is limited once a hospital owns a compatible platform.

Targeted or higher-contrast next-generation dyes could improve sentinel node accuracy and reduce ambiguity in obese or complex cases.

3.4 Bile duct identification

This is one of the most practical and high-frequency use cases in general surgery. ICG-enabled fluorescence cholangiography is now a standard reference workflow in many laparoscopic and robotic cholecystectomy settings, especially as an adjunct to white light.

For LumiSurg, biliary imaging matters because:

  • it is a large-volume procedure class;
  • surgeons understand the value immediately;
  • it creates a natural entry point for any improved structure-specific dye.

3.5 Adjacent high-value use case: ureter mapping

Even though it was not in the original application list, ureter identification deserves attention because it is one of the clearest opportunities for differentiated dyes such as ZW800-1/nizaracianine or MB-based workflows. A product that reduces ureteral injury risk during pelvic and colorectal surgery has straightforward economic and medicolegal appeal.

4. Key players

4.1 Device and platform players

Player Relevance
Stryker Major installed-base player through SPY fluorescence platforms for perfusion and intraoperative assessment
Olympus Broad surgical imaging platform provider; strategically strengthened by acquiring Quest Photonic Devices
Hamamatsu Long-standing imaging component and system leader, including PDE-Neo II fluorescence imaging products
Quest Medical Imaging / Quest Photonic Devices Important multispectral and fluorescence-guided surgery platform company, now within Olympus
Intuitive Surgical Not in the original list, but highly relevant because Firefly is one of the most influential fluorescence-enabled robotic workflows

4.2 Agent and translational players

Player Relevance
On Target Laboratories Most important pure-play example in approved targeted surgical fluorescence through CYTALUX
Diagnostic Green and other ICG suppliers Critical incumbents because ICG remains the practical standard
LI-COR Biosciences Important through IRDye 800CW chemistry and translational ecosystem
Academic translational centers and CROs Still disproportionately influential because many dye programs remain trial-driven rather than fully commercial

4.3 Note on "Intuity Medical"

Public-source review does not show Intuity Medical as a meaningful player in fluorescence-guided surgery. Its public commercial footprint is associated with glucose monitoring products, not operative fluorescence imaging. The likely intended company is Intuitive Surgical, whose Firefly platform is directly relevant to fluorescence-guided surgery.

5. Regulatory landscape

5.1 FDA

The FDA pathway is the clearest global reference point for operative fluorescent agents:

  • ICG is long approved and now carries modern surgical imaging indications tied to perfusion, biliary imaging, and lymphatic mapping on approved labeling.
  • CYTALUX provides a concrete precedent for targeted optical imaging approval in oncology.
  • Device compatibility matters: drug labels and imaging system clearances are often operationally linked.
  • MB is approved as a drug, but many fluorescence-surgery uses are still off-label rather than productized around a dedicated labeled indication.

For new dyes, the regulatory challenge is usually not just the molecule. Sponsors must align:

  • CMC package;
  • toxicology;
  • imaging-system compatibility;
  • operative training and instructions for use;
  • pivotal endpoints that show incremental surgical value.

5.2 EMA and Europe

In Europe, the picture is more fragmented:

  • the EMA manages centralized medicine review, but many products still reach market through national authorization routes;
  • indocyanine green is clearly present in Europe through nationally authorized products such as Verdye and EMA pharmacovigilance records for indocyanine green;
  • public review of the EU Union Register does not identify a centralized EU marketing authorization for pafolacianine, IRDye 800CW, or ZW800-1 as of 2026-04-24.

That suggests Europe remains commercially earlier than the U.S. for novel targeted operative fluorophores, even though device availability and investigator-led clinical work are strong.

5.3 Practical regulatory implications for LumiSurg

If LumiSurg eventually expands beyond intelligence and into product strategy, the de-risking hierarchy is likely:

  1. Known-dye optimization or relabeling around validated workflows.
  2. Structure-specific dyes with clear intraoperative utility and manageable endpoints.
  3. Targeted oncology fluorophores with stronger upside but higher development complexity.
  4. True NIR-II novel entities, which offer the highest long-term differentiation but the heaviest translational burden.

6. Market size and growth, 2024-2030

6.1 What can be said with confidence

  • The fluorescence-guided surgery market is growing faster than many mature medtech categories.
  • Growth is being supported by robotic surgery, minimally invasive workflows, demand for complication reduction, and broader surgeon familiarity with fluorescence.
  • Hardware adoption currently leads revenue stability; dye innovation is the main upside variable.

6.2 What cannot yet be said confidently

There is no reliable public consensus estimate for a standalone NIR-II surgical contrast-agent market from 2024 to 2030. Most published numbers either:

  • describe fluorescence-guided surgery systems only;
  • combine devices and reagents into wider NIR imaging markets;
  • or do not distinguish NIR-I from NIR-II.

6.3 LumiSurg house view

The most realistic internal view is:

  • 2024-2027: market revenue remains concentrated in ICG-centric workflows and installed camera systems;
  • 2026-2030: targeted fluorescence agents continue to expand, especially in oncology and anatomy-specific niches;
  • through 2030, true NIR-II contrast agents are more likely to emerge first as premium, high-value niches than as a mass-market replacement for ICG.

7. Unmet needs and opportunities

7.1 Unmet needs

  • Better specificity than ICG for tumor biology and structure identification.
  • More robust performance in deep tissue and bloody operative fields.
  • Standardized quantitative readouts rather than subjective fluorescence interpretation.
  • Ambient-light-compatible NIR-II imaging systems for routine OR use.
  • Cleaner regulatory playbooks for drug-device-software combinations.
  • Better evidence linking fluorescence to hard outcomes, reimbursement, and hospital ROI.

7.2 Highest-value opportunity areas

Opportunity area Why it matters
Tumor-targeted oncology dyes Highest pricing power and strongest differentiation from ICG
Ureter / nerve / bile-specific dyes Solves discrete surgical-risk problems with clear workflow value
NIR-II-compatible agents using familiar safety scaffolds Lowest-friction bridge from current NIR-I practice
Device-agent interoperability intelligence Hospitals and developers need practical compatibility maps
Regulatory and clinical intelligence platform The market is fragmented; centralization itself has value
Quantification and decision-support layers Software can make fluorescence more reproducible and defensible

7.3 Best initial positioning for LumiSurg

LumiSurg should position itself as the specialist intelligence layer for this market before trying to behave like a full product company. The strongest near-term moat is centralizing:

  • clinical evidence by indication and dye;
  • regulatory status by geography;
  • imaging-system compatibility;
  • public and private player tracking;
  • translational signal around NIR-II agents moving from lab to OR.

That positioning is consistent with the current maturity of the market and gives LumiSurg a credible base for later BD, consulting, licensing, or product incubation.

8. Recommended follow-up work

  1. Build a structured database of surgical fluorophores with fields for wavelength, target, clearance route, clinical stage, geography, imaging-system compatibility, and surgical indication.
  2. Track all active clinical trials for IRDye 800CW conjugates, ZW800-1 / nizaracianine, pafolacianine follow-ons, and true NIR-II candidates.
  3. Produce a separate device landscape note covering Firefly, SPY, Quest Spectrum, Olympus, Hamamatsu, Karl Storz, and ambient-light NIR-II entrants.
  4. Create a regulatory matrix comparing FDA, EMA/national-EU, UK, and Asia pathways for operative fluorescence agents.
  5. Add a company watchlist for On Target Laboratories, Diagnostic Green, LI-COR, Quest/Olympus, Stryker, and translational spin-outs developing NIR-II probes.

Source notes

This document is based on public sources reviewed on 2026-04-24. Commercial market estimates vary by scope and should be treated as directional, not precise. The most reliable public signals for this topic remain official drug labels, regulator pages, company product pages, ClinicalTrials.gov records, and recent peer-reviewed reviews.

Selected sources

← Retour à l'Intelligence Documentaire